Variability in abciximab (ReoPro®) prescribing: evidence based or budget driven?

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2002-03-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1002/PDS.689PMID 11998538
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?

  2000cited by this paper
• Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961

  2000cited by this paper
• Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

  1999cited by this paper
• Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

  1999cited by this paper
• Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.

  1999cited by this paper
• Economic considerations in the use of the platelet GP IIb/IIIa inhibitor abciximab in percutaneous coronary intervention

  1999cited by this paper
• Challenges to the Economic Evaluation of New Biotechnological Interventions in Healthcare

  1999cited by this paper
• Assessment of biotechnology drugs: what are the issues?

  1999cited by this paper
• Assessment of biotechnology drugs: what are the issues?

  1999cited by this paper
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

  1998cited by this paper
• [Abciximab: a new antiplatelet agent for use in coronary angioplasty].

  1998cited by this paper
• Abciximab therapy in percutaneous intervention: economic issues in the United States.

  1998cited by this paper
• Cost and outcomes analysis of abciximab use in a community teaching hospital.

  1998cited by this paper
• Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

  1998cited by this paper
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

  1998cited by this paper
• Marketing medicines through randomised controlled trials: the case of interferon

  1998cited by this paper
• Lipid-lowering therapy in low-risk patients.

  1998cited by this paper
• Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.

  1998cited by this paper
• Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.

  1998cited by this paper
• Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.

  1998cited by this paper
• Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators.

  1998cited by this paper
• A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)

  1998cited by this paper
• Routine use of abciximab in coronary stenting?

  1998cited by this paper
• Enthusiasm, reality, and cost-effectiveness analysis

  1998cited by this paper
• Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.

  1998cited by this paper
• Abciximab: een nieuwe plaatjesaggregatieremmer voor toepassing bij coronaire angioplastiek

  1998cited by this paper
• Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.

  1998cited by this paper
• Abciximab

  1998cited by this paper
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.

  1997cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

  1997cited by this paper
• Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.

  1997cited by this paper
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

  1997cited by this paper
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention : IMPACT-II

  1997cited by this paper
• Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands.

  1995cited by this paper
• Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease.

  1994cited by this paper
• Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina

  1994cited by this paper
• Prevention of coronary heart disease in clinical practice

  1994cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction.

  1992cited by this paper
• Outcomes research, cost containment, and the fear of health care rationing.

  1990cited by this paper
• Diffusion of innovations

  1964cited by this paper

• Rare disease patients’ needs: an up-to-date analysis and future directions

  2021cites this paper
• Pharmacoepidemiology and drug safety.

  2002cites this paper
• Current Awareness: Pharmacoepidemiology and Drug Safety

  2002cites this paper